表紙
市場調查報告書

性狀轉換成長因素β1 (TGFB1) :開發中產品分析

Transforming Growth Factor Beta 1 - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 368726
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
性狀轉換成長因素β1 (TGFB1) :開發中產品分析 Transforming Growth Factor Beta 1 - Pipeline Review, H2 2020
出版日期: 2020年07月31日內容資訊: 英文 102 Pages
簡介

本報告提供以性狀轉換成長因素β1 (TGFB1) 為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

性狀轉換成長因素β1 (TGFB1) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Acceleron Pharma Inc
  • Eli Lilly and Company
  • Genzyme Corp
  • Huabo Biopharm Co Ltd
  • Isarna Therapeutics GmbH
  • Johnson & Johnson
  • Novartis AG
  • Scholar Rock Inc
  • Sirnaomics Inc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2504TDB

Summary:

Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-B1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.

Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 31 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 1, 12 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Ophthalmology, Respiratory, Gastrointestinal, Dermatology, Genito Urinary System And Sex Hormones, Immunology, Cardiovascular, Central Nervous System, Genetic Disorders, Hematological Disorders, Infectious Disease, Male Health and Metabolic Disorders which include indications Fibrosis, Idiopathic Pulmonary Fibrosis, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Corneal Dystrophy, Hepatocellular Carcinoma, Kidney Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Osteoarthritis, Primary Sclerosing Cholangitis, Squamous Cell Carcinoma, Acute Respiratory Distress Syndrome, Age Related Macular Degeneration, Anemia, Benign Prostatic Hyperplasia, Bladder Cancer, Bone Disorders, Cholangitis, Coronavirus Disease 2019 (COVID-19), Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hyperalgesia, Hypertrophic Scars, Inflammation, Keloids, Liver Fibrosis, Lung Adenocarcinoma, Melanoma, Metastatic Breast Cancer, Myelofibrosis, Nonmelanomatous Skin Cancer, Open-Angle Glaucoma, Osteogenesis Imperfecta, Pancreatic Cancer, Pancreatitis Pain, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Proliferative Vitreoretinopathy (PVR), Pulmonary Hypertension, Scar, Systemic Sclerosis (Scleroderma), Transitional Cell Cancer (Urothelial Cell Cancer) and Triple-Negative Breast Cancer (TNBC).

The latest report Transforming Growth Factor Beta 1 - Pipeline Review, H2 2020, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
  • The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

  • Introduction
  • Transforming Growth Factor Beta 1 (TGFB1) - Overview
  • Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Development
  • Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment
  • Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development
  • Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles
  • Transforming Growth Factor Beta 1 (TGFB1) - Dormant Products
  • Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products
  • Transforming Growth Factor Beta 1 (TGFB1) - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Aiviva BioPharma Inc, H2 2020
  • Pipeline by Avacta Life Sciences Ltd, H2 2020
  • Pipeline by Avellino Lab USA Inc, H2 2020
  • Pipeline by Bonac Corp, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Dormant Products, H2 2020 (Contd..2), H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020